Title: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
Authors: De Vleeschouwer, Steven ×
Fieuws, Steffen
Rutkowski, Stefan
Van Calenbergh, Frank
van Loon, Johan
Goffin, Jan
Sciot, Raphael
Wilms, Guy
Demaerel, Philippe
Warmuth-Metz, Monika
Soerensen, Niels
Wolff, Johannes E A
Wagner, Sabine
Kaempgen, Eckhart
Van Gool, Stefaan #
Issue Date: May-2008
Publisher: Association for Cancer Research
Series Title: Clinical Cancer Research vol:14 issue:10 pages:3098-3104
Abstract: PURPOSE: To investigate the therapeutic role of adjuvant vaccination with autologous mature dendritic cells (DC) loaded with tumor lysates derived from autologous, resected glioblastoma multiforme (GBM) at time of relapse. EXPERIMENTAL DESIGN: Fifty-six patients with relapsed GBM (WHO grade IV) were treated with at least three vaccinations. Children and adults were treated similarly in three consecutive cohorts, with progressively shorter vaccination intervals per cohort. Feasibility and toxicity were assessed as well as effect of age, extent of resection, Karnofsky Performance Score, and treatment cohort on the progression-free (PFS) and overall survival (OS) using univariable and multivariable analysis. RESULTS: Since the prevaccine reoperation, the median PFS and OS of the total group was 3 and 9.6 months, respectively, with a 2-year OS of 14.8%. Total resection was a predictor for better PFS both in univariable analysis and after correction for the other covariates. For OS, younger age and total resection were predictors of a better outcome in univariable analysis but not in multivariable analysis. A trend to improved PFS was observed in favor of the faster DC vaccination schedule with tumor lysate boosting. Vaccine-related edema in one patient with gross residual disease before vaccination was the only serious adverse event. CONCLUSION: Adjuvant DC-based immunotherapy for patients with relapsed GBM is safe and can induce long-term survival. A trend to PFS improvement was shown in the faster vaccination schedule. The importance of age and a minimal residual disease status at the start of the vaccination is underscored.
ISSN: 1078-0432
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Pediatric Hematology & Oncology Section (-)
Research Group Experimental Neurosurgery and Neuroanatomy
Translational Cell & Tissue Research
Laboratory of Pediatric Immunology
Laboratory of Clinical Immunology
Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat)
Translational MRI (+)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
ClinCancher_Postoperative_full.pdf Published 142KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science